Sleep, Anxiety, and Hormonal Balance

How the bitter compounds in hops — humulone, xanthohumol, and 8-prenylnaringenin — calm the nervous system, improve sleep quality, and support hormonal health through GABA and estrogen receptor pathways.

Hops (Humulus lupulus) are best known as the bittering agent in beer, but the dried female flower cones have been used as a medicinal herb for over a thousand years — historically stuffed into pillows to aid sleep and brewed into calming teas for nervous tension. Modern research has identified specific compounds in hops that work directly on GABA receptors in the brain, the same system targeted by pharmaceutical sleep and anxiety medications, but through a gentler, non-addictive mechanism [1][2]. There is also meaningful evidence that hops contain one of the most potent plant estrogens known, making it a candidate for natural menopause symptom relief [5].

How Hops Works

Three distinct compound families in hops contribute to its health effects:

Alpha acids (humulone and cohumulone) are the primary bitter compounds in hops and the best-studied sleep agents. Humulone has been shown to act as a positive allosteric modulator of GABA-A receptors — meaning it makes these receptors more sensitive to the brain's own calming neurotransmitter (GABA) without directly activating them [2]. In laboratory studies, humulone shortened sleep onset, extended sleep duration, and increased deep slow-wave sleep in a dose-dependent manner. This mechanism parallels how valerian works, which explains why the two herbs are so often combined in sleep formulas.

Xanthohumol is a prenylated flavonoid unique to hops that has demonstrated anti-inflammatory, antioxidant, and potentially metabolic benefits in animal and cell studies [6]. It is present at low levels in finished beer but concentrated in hop supplements and extracts.

8-Prenylnaringenin (8-PN) is a phytoestrogen produced when hops are processed or aged, and is considered one of the most potent plant-derived estrogens identified — roughly 0.2–20% the binding affinity of estradiol at estrogen receptors [5]. This gives hops a potential role in menopausal symptom relief, particularly hot flashes, for women who prefer not to use pharmaceutical hormone therapy.

Practical Use

For sleep: Hops extract is most commonly combined with valerian root. A randomized controlled trial found the combination significantly superior to placebo in reducing sleep latency, while valerian alone did not show a significant benefit — suggesting a synergistic effect [3]. A typical dose is 60–120 mg of hops standardized extract alongside 300–500 mg valerian, taken 30–60 minutes before bed.

For anxiety and stress: A crossover trial in healthy young adults found that 4 weeks of hops dry extract (400 mg/day) reduced anxiety scores by approximately 45%, depression scores by 22%, and stress scores by 39% on the validated DASS-21 scale — all significantly superior to placebo [4].

For menopause: Standardized extracts containing 100 µg of 8-prenylnaringenin daily have been studied in clinical trials. A double-blind RCT in 67 menopausal women found significant reduction in hot flush scores at 6 weeks (P < 0.01 vs. placebo) [5]. Notably, the lower dose (100 µg) outperformed the higher dose (250 µg), suggesting a bell-curve dose-response typical of phytoestrogen activity.

Forms available:

Standardized capsules or tablets (commonly combined with valerian, lemon balm, or passionflower)
Liquid tinctures
Dried strobiles for tea (traditional use)

Precautions: Like valerian, hops may potentiate the effects of alcohol and sedative medications. Women with estrogen-sensitive conditions (ER-positive breast cancer history, endometriosis, uterine fibroids) should consult a healthcare provider before using hops regularly given its phytoestrogen content. Not recommended during pregnancy or for children.

See our valerian page for a closely related herb, or our passionflower page for another GABA-modulating plant with a complementary mechanism.

Evidence Review

Mechanistic Research

The clearest mechanistic work on hops comes from Benkherouf et al. (2020), who used a combination of electrophysiology, radioligand binding, and in vivo behavioral studies to characterize humulone's action on GABA-A receptors [2]. Key findings:

Humulone potentiated GABA-induced currents at the alpha1-beta3-gamma2 receptor subtype, one of the most abundant GABA-A configurations in the brain
Potentiation occurred at low micromolar concentrations, consistent with therapeutic tissue concentrations achievable from supplements
In behavioral assays (mice), humulone shortened sleep onset time, extended pentobarbital-induced sleep duration in a dose-dependent manner, and reduced spontaneous locomotion at 20 mg/kg intraperitoneally
The authors concluded humulone is the primary active compound responsible for hops' sleep-promoting activity

An earlier experimental study by Franco et al. (2012) demonstrated that non-alcoholic hop extract administered to nursing students working rotating shifts reduced daytime activity levels and improved circadian rest patterns, with effects mediated through 2-methyl-3-buten-2-ol (MBE), a volatile compound derived from humulone during metabolism [1]. This was among the first published human evidence for hops acting on the sleep-wake cycle.

Clinical Trials: Sleep

Koetter et al. (2007) conducted a rigorous double-blind, placebo-controlled RCT in patients with diagnosed non-organic sleep disorder [3]. Patients received either a fixed combination of valerian-hops extract (Ze 91019) or placebo, with sleep objectively measured using QUISI home recorders. The valerian-hops combination was significantly superior to placebo in reducing sleep latency. Critically, a valerian-alone arm also failed to beat placebo in this trial, pointing to genuine synergy between the two herbs rather than either acting alone.

Clinical Trials: Anxiety and Mood

Kyrou et al. (2017) conducted a 4-week randomized, placebo-controlled, double-blind crossover study in 36 healthy young adults (mean age 24.7 years) using 400 mg/day of hops dry extract [4]. Using the validated Depression Anxiety Stress Scale (DASS-21), they found:

Anxiety subscale: reduced from 9.2 ± 7.3 to 5.1 ± 5.9 (p < 0.05) — approximately 45% reduction
Depression subscale: decreased from 11.9 ± 7.9 to 9.2 ± 7.4 (p < 0.05)
Stress subscale: reduced from 19.1 ± 8.1 to 11.6 ± 8.1 (p < 0.05) — approximately 39% reduction

All improvements were significantly greater than the placebo period. The crossover design strengthens these findings by controlling for inter-individual variability. Limitations include the small sample size and the relatively young, healthy population, which may not generalize to clinical anxiety disorders.

Clinical Trials: Menopause

Heyerick et al. (2006) conducted the first prospective RCT of a standardized hop extract for menopausal discomforts [5]. Sixty-seven menopausal women were randomized to 100 µg 8-PN, 250 µg 8-PN, or placebo for 12 weeks, with symptoms assessed using the Menopause Rating Scale and specific hot flush diaries. Results:

Both active treatment groups showed significant symptom reduction from baseline at 6 and 12 weeks
The 100 µg dose was significantly superior to placebo at 6 weeks (P = 0.023)
Hot flush scores specifically were significantly reduced at 6 weeks in both treatment groups (P < 0.01 vs. placebo)
The paradoxical finding that 100 µg outperformed 250 µg is consistent with known phytoestrogen biology, where higher receptor occupancy can reduce rather than amplify effect

The animal mechanistic basis was established by Bowe et al. (2006, PMID 17088409), who showed 8-PN at 400 µg/kg reversed the rise in skin temperature in ovariectomized rats — an established hot flush model — and that this effect was fully blocked by an estrogen receptor antagonist, confirming ER-mediated action.

Metabolic and Anti-Inflammatory Evidence

Dostálek et al. (2017) reviewed evidence for hop phytochemicals in metabolic syndrome [6]. Xanthohumol demonstrated hypoglycemic, antihyperlipidemic, and antiobesity effects in animal models. Iso-alpha-acids (IAAs) improved lipid metabolism, glucose tolerance, and body weight in rodent studies. The reviewers note these findings are promising but await large human clinical trials to confirm translation from animal data.

Strength of Evidence

The evidence for hops as a sleep aid is moderate, supported by established mechanisms (GABA-A modulation) and multiple RCTs, though many trials test the valerian-hops combination rather than hops alone. For anxiety, the single human RCT is small and uses a healthy population. For menopausal hot flashes, the evidence is moderate-strong with one well-designed RCT and solid mechanistic backing. Metabolic effects remain primarily preclinical. Overall, hops' safety profile is well-established and adverse events in trials have been rare and mild.

References

The sedative effects of hops (Humulus lupulus), a component of beer, on the activity/rest rhythmFranco L, Sánchez C, Bravo R, Rodriguez A, Barriga C, Cubero Juánez J. Acta Physiologica Hungarica, 2012. PubMed 22849837 →
Humulone Modulation of GABAA Receptors and Its Role in Hops Sleep-Promoting ActivityBenkherouf AY, Eerola K, Soini SL, Uusi-Oukari M. Frontiers in Neuroscience, 2020. PubMed 33177986 →
A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorderKoetter U, Schrader E, Käufeler R, Brattström A. Phytotherapy Research, 2007. PubMed 17486686 →
Effects of a hops (Humulus lupulus L.) dry extract supplement on self-reported depression, anxiety and stress levels in apparently healthy young adults: a randomized, placebo-controlled, double-blind, crossover pilot studyKyrou I, Christou A, Panagiotakos D, Stefanaki C, Skenderi K, Katsana K, Tsigos C. Hormones (Athens), 2017. PubMed 28742505 →
A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomfortsHeyerick A, Vervarcke S, Depypere H, Bracke M, De Keukeleire D. Maturitas, 2006. PubMed 16321485 →
Hop Phytochemicals and Their Potential Role in Metabolic Syndrome Prevention and TherapyDostálek P, Karabín M, Jelínek L. Molecules, 2017. PubMed 29048380 →